CEDAR KNOLLS, N.J., April 24, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a company focused on the discovery, development and commercialization of muscle health and performance products, announced today that it will be a Silver Sponsor at the upcoming International Conference on Frailty and Sarcopenia Research (ICFSR), to be held April 27-29, 2017 in Barcelona, Spain. MYOS will be using this event as a platform for introducing clinicians to Qurr Well, their new line of functional nutrition products targeted at improving musculoskeletal health in aging adults.
"We are pleased to be a sponsor at the upcoming International Conference on Frailty and Sarcopenia Research, and to have the opportunity to showcase the Qurr Well portfolio of products that may provide a solution to age-related muscle loss in adults by increasing lean muscle mass," stated Joseph Mannello, interim CEO of MYOS. "With this portfolio of products, MYOS aspires to become one of the leading companies in the world focused on improving musculoskeletal health in aging adults."
The ICFSR is the premier medical conference that highlights advances in sarcopenia research, with over 400 leading physicians and scientists with expertise in sarcopenia from 62 countries attending each year. Sarcopenia is defined by the National Institutes of Health as the progressive and generalized loss of skeletal muscle mass and function in older adults, and MYOS will be joining other companies focused on addressing sarcopenia through therapeutics and nutrition at the conference.
Qurr Well, along with the entire Qurr portfolio of products, features Fortetropin®, which has been clinically shown to build lean muscle mass and improve muscle function. Fortetropin® is MYOS' proprietary ingredient that naturally reduces myostatin. It is prepared from fertilized egg yolk and is processed using patented technology to preserve the natural bioactivity of egg yolk. Results from a double-blind, placebo-controlled human clinical study with researchers from the University of Tampa demonstrated statistically significant gains in muscle thickness relative to placebo. Qurr products come in shakes and powders and are available in four flavors.
MYOS will exhibit in booth #2 at ICFSR 2017, and its scientists will be in attendance to meet with conference delegates to discuss the Company's latest research findings. For more information or to purchase Qurr, please visit www.qurr.com.
About MYOS RENS Technology Inc.
MYOS RENS Technology (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based biotherapeutics and bionutrition company focused on developing products that improve muscle health and performance and bringing them to market. MYOS is the owner of Fortetropin®, the world's first clinically demonstrated myostatin reducer. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Fortetropin® is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful launch of our products, including Qurr products, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into partnership opportunities, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.
MYOS RENS Technology Inc.
SOURCE MYOS RENS Technology